Risk Isn't Inevitable: How The Right CDMO Partnership Protects Your Programme

By Lorna Patrick, Chief Operating Officer, Upperton

Risk is often viewed as an unavoidable part of drug development, yet in many CDMO partnerships it is intensified by operational design rather than scientific uncertainty. Structural choices around team continuity, ownership, and communication can either magnify complexity or help control it. Risk frequently enters through fragmented teams, repeated handoffs, and siloed project management—issues that tend to surface only after timelines slip or costs rise. Integrated, cross‑functional teams with consistent programme ownership preserve institutional knowledge and enable earlier identification of both scientific and operational challenges. Facility design, collaboration models, and the quality of sponsor–CDMO communication emerge as practical drivers of risk, not abstract considerations.

For biotech teams working under tight timelines and limited internal resources, evaluating partners through this lens helps distinguish those that manage complexity proactively from those that allow uncertainty to accumulate as programmes move toward the clinic and beyond.